EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo

James Logue, Victoria M Melville, Jeremy Ardanuy, Matthew B Frieman iD

PLOS Pathogens · 2023

DOI: 10.1371/journal.ppat.1011870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2023. Verfasst von James Logue und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, Maryland, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic has claimed over 6.5 million lives worldwide and continues to have lasting impacts on the world’s healthcare and economic systems. Several approved and emergency authorized therapeutics that inhibit early stages of the virus replication cycle have been developed however, effective late-stage therapeutical targets have yet to be identified. To that end, our lab identified that 2’,3’ cyclic-nucleotide 3’-phosphodiesterase (CNP) inhibits SARS-CoV-2 virion assembly. We show that CNP inhibits the generation of new SARS-CoV-2 virions, reducing intracellular titers without inhibiting viral structural protein translation. Additionally, we show that targeting of CNP to mitochondria is necessary for inhibition, blocking mitochondrial depolarization and implicating CNP’s proposed role as an inhibitor of the mitochondrial permeabilization transition pore (mPTP) as the mechanism of virion assembly inhibition. We also demonstrate that an adenovirus expressing virus expressing both human ACE2 and CNP inhibits SARS-CoV-2 titers to undetectable levels in lungs of mice. Collectively, this work shows the potential of CNP to be a new SARS-CoV-2 antiviral target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19MiceHumansAnimalsPandemicsMitochondriaVirus AssemblyAntiviral Agents

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • The Department of Microbiology and Immunology, The University of Maryland School of Medicine, Baltimore, Maryland, United States of America.
  • Center for Pathogen Research, The University of Maryland School of Medicine, Baltimore, Maryland, United States of America.

ORCID-Profile: Matthew B Frieman

Förderung

  • NIAID NIH HHS
  • Division of Intramural Research, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Logue, J., Melville, V. M., Ardanuy, J., & Frieman, M. B. (2023). CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011870

Vancouver

Logue J, Melville VM, Ardanuy J, Frieman MB. CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo. PLOS Pathogens. 2023. doi:10.1371/journal.ppat.1011870

BibTeX
@article{Logue2023,
  author = {Logue, James and Melville, Victoria M and Ardanuy, Jeremy and Frieman, Matthew B},
  title = {CNP blocks mitochondrial depolarization and inhibits SARS-CoV-2 replication in vitro and in vivo},
  journal = {PLOS Pathogens},
  year = {2023},
  doi = {10.1371/journal.ppat.1011870}
}
Kostenlos starten →